1-(2-Hydroxy-ethyl)-2,2,6,6-tetramethyl-piperidin | 773-51-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-(2-Hydroxy-ethyl)-2,2,6,6-tetramethyl-piperidin
• 英文别名: 1-(2-Hydroxyethyl)-2,2,6,6-tetramethylpiperidine；2-(2,2,6,6-tetramethylpiperidin-1-yl)ethanol
• CAS: 773-51-3
• 化学式: C₁₁H₂₃NO
• 分子量: 185.31
• InChiKey: KHQLVIVUNHQCJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-Hydroxy-ethyl)-2,2,6,6-tetramethyl-piperidin 、 2,2,6,6-Tetramethyl-1-{2-[(oxiran-2-yl)methoxy]ethyl}piperidine 生成 二缩水甘油醚
  参考文献：
  名称：

  Polyalkylpiperidinesulfonic acid esters

  摘要：

  公式I和II B--X--O--SO.sub.2 --A).sub.m (I) (B'--X--O--SO.sub.2).sub.2 A' (II)的聚烷基哌啶磺酸酯，其中A、A'、B、B'、X和m的定义如权利要求书中所述，聚烷基哌啶基团存在于取代基B和B'中的每一个。这些酯类适用于作为酸可固化树脂的固化催化剂，并在其中起到光稳定剂的作用。

  公开号：

  US04537923A1
• 作为产物：
  描述：

  oxo-(2,2,6,6-tetramethyl-piperidin-1-yl)-acetic acid ethyl ester 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以100%的产率得到1-(2-Hydroxy-ethyl)-2,2,6,6-tetramethyl-piperidin
  参考文献：
  名称：

  EP1566379

  摘要：

  公开号：

文献信息

• Indazole compounds and methods of use thereof
  申请人：Bhagwat S. Shripad

  公开号：US20060004043A1

  公开（公告）日：2006-01-05

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防广泛的疾病和紊乱方面具有实用性，这些疾病和紊乱对激酶的抑制、调节或调控具有反应性，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病有关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛和其他疾病。因此，本发明还揭示了治疗或预防此类疾病和紊乱的方法，以及包含一种或多种吲唑化合物的药物组成物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，它们在蛋白激酶调节方面具有强效活性。因此，本发明包括口服活性分子以及可用于治疗与蛋白激酶信号转导相关的疾病或紊乱的肠外活性分子，其剂量或血清浓度较低。
• Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
  申请人：Miwa Atsushi

  公开号：US20080207617A1

  公开（公告）日：2008-08-28

  An objective of the present invention is to provide compounds and pharmaceuticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R 1 , R 2 , and R 3 represent H, OH, or optionally substituted alkoxy; R 4 represents H; R 5 , R 6 , R 7 , and R 8 represent H, Hal, alkyl or the like; and R 9 represents, e.g., alkyl substituted by t-butyl or the like.

  本发明的目标是提供化合物和药物，用于治疗抑制FMS样酪氨酸激酶3（Flt3）自磷酸化在治疗上具有疗效的疾病。本发明涉及一种药物组合物，用于治疗或预防抑制Flt3自磷酸化在治疗或预防上具有疗效的疾病，所述药物组合物包括以下公式（I）所表示的化合物或其药学上可接受的盐或溶剂：其中X代表CH或N；Z代表O或S；R1、R2和R3代表H、OH或可选取代的烷氧基；R4代表H；R5、R6、R7和R8代表H、卤素、烷基或类似物；R9代表例如被t-丁基或类似物取代的烷基。
• INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Bhagwat Shripad S.

  公开号：US20090099178A1

  公开（公告）日：2009-04-16

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseases or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防许多对激酶的抑制、调节或调控具有反应性的疾病和障碍方面具有用途，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病相关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还揭示了治疗或预防这些疾病和障碍的方法，以及包含一种或多种吲唑化合物的制药组合物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，这些分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和经肠道给药的活性分子，可用于治疗与蛋白激酶信号转导相关的疾病或障碍，且可用较低剂量或血清浓度。
• TRANSPARENT POLYMER ARTICLES OF LOW THICKNESS
  申请人：LEPPARD DAVID GEORGE

  公开号：US20100178484A1

  公开（公告）日：2010-07-15

  The novel transparent polyolefin or polyamide article disclosed is stabilized against the effects of light, oxygen, heat and agressive chemicals by addition of 0.005-0.30% by weight the polymeric substrate of a hydroxyphenyl triazine UV absorber, and is characterized by its thickness between 1 and 500 μm. Preferred polyolefin articles thus stabilized are agricultural films containing as further stabilizer a sterically hindered amine. The novel compositions act as selective UV filter especially useful in agriculture.

  所披露的透明聚烯烃或聚酰胺材料经过添加0.005-0.30%重量的羟基苯基三嗪紫外线吸收剂进行稳定，以抵抗光、氧、热和侵蚀性化学物质的影响，并以其厚度在1至500μm之间的特点而闻名。因此，优选稳定的聚烯烃材料是农业薄膜，其中还包含了一个立体阻碍胺作为进一步的稳定剂。这种新型组合物作为选择性紫外线过滤器，在农业中特别有用。
• Malonsäurederivate von sterisch gehinderten Piperidinen, Verfahren zu ihrer Herstellung und mit ihnen stabilisiertes organisches Material
  申请人：CIBA-GEIGY AG

  公开号：EP0002260A2

  公开（公告）日：1979-06-13

  Malonsäurederivate der Formel worin Z eine sterisch gehinderte Piperidingruppe enthält, als Stabilisatoren gegen lichtinduzierten Abbau von organischem Material.

  式中的丙二酸衍生物 其中 Z 含有一个立体受阻的哌啶基团，可作为稳定剂防止光引起的有机材料降解。